NCT04968613View on ClinicalTrials.gov

Dopaminergic Mechanism of Memory Impairment in Parkinson's Disease

PHASE4UnknownINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

January 1, 2018

Primary Completion Date

December 31, 2021

Study Completion Date

December 31, 2021

Conditions
Parkinson DiseaseMemory Impairment
Interventions
DRUG

Madopar monotherapy

In addition to basic treatment, the patient also received Madopar treatment

DRUG

senfrol monotherapy

In addition to the basic treatment, the patient also received the rofosson treatment

DRUG

placebo monotherapy

In addition to basic treatment, the patient also received selegiline treatment

Trial Locations (1)

Unknown

RECRUITING

Peking University Third Hospital, Beijing

Sponsors
All Listed Sponsors
collaborator

Chinese Academy of Sciences

OTHER_GOV

lead

Peking University Third Hospital

OTHER

NCT04968613 - Dopaminergic Mechanism of Memory Impairment in Parkinson's Disease | Biotech Hunter | Biotech Hunter